Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma


In Partnership With:

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Joseph Mikhael, MD, professor, Applied Cancer Research and Drug Discovery Division, Translational Genomics Research Institute (TGen), an affiliate of City of Hope Cancer Center, chief medical officer, International Myeloma Foundation, discusses remaining challenges in high-risk multiple myeloma.

Within the past decade, the average survival of patients with multiple myeloma has significantly improved compared with historic rates, says Mikhael. However, survival has not been improved to the same degree in patients with high-risk disease.

Additionally, patients with extramedullary disease, who can also be considered high risk, remain a challenging patient population to treat, Mikhael explains. Extramedullary disease presents de novo outside of the medullary space. Moreover, these patients can be challenging to image, measure, and treat as they may have heavy disease burden. Future research efforts should aim to identify a treatment strategy for patients with extramedullary disease, concludes Mikhael.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center